On June 3, Medtronic rose 4.76% in regular trading, trading at $76.91/share, with trading volume of $191 million. The rally was driven by the release of fiscal Q4 and full-year results that delivered the company's strongest annual revenue growth in the past decade.

Specifically, Medtronic reported fiscal Q4 revenue of $9.807 billion, surpassing the consensus estimate of $9.635 billion. The core Cardiovascular Portfolio segment was a standout performer, with sales surging 13.8% year-over-year fueled by robust demand for its pulsed field ablation product portfolio. However, adjusted EPS of $1.50 came in below the $1.54 consensus, representing a 7.41% year-over-year decline. For fiscal 2027, the company guided adjusted EPS of $5.90 to $6.00.

Additionally, Medtronic announced strategic investments in two privately held intracardiac echocardiography catheter companies to support the expansion of its cardiac ablation portfolio, and filed a 510(K) application to expand its Hugo robotic-assisted surgery system into general surgery and gynecology in the U.S. The market focused on revenue upside and accelerating new product cycle momentum over the modest EPS shortfall.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)